Brokers Issue Forecasts for SAGE FY2029 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for shares of Sage Therapeutics in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will post earnings of $0.35 per share for the year. Wedbush currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.47) per share.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.81) earnings per share.

A number of other research analysts have also issued reports on SAGE. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price for the company in a research note on Thursday, November 21st. Oppenheimer reduced their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, October 30th. TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Thursday, November 21st. Piper Sandler reduced their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Finally, Scotiabank reduced their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research note on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Sage Therapeutics currently has an average rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Stock Up 1.1 %

Sage Therapeutics stock opened at $7.10 on Friday. The firm has a 50-day moving average price of $5.83 and a two-hundred day moving average price of $7.37. The firm has a market capitalization of $434.31 million, a price-to-earnings ratio of -1.27 and a beta of 0.91. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $27.67.

Institutional Investors Weigh In On Sage Therapeutics

Large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares during the period. Creative Planning acquired a new stake in shares of Sage Therapeutics during the third quarter valued at approximately $88,000. Point72 DIFC Ltd acquired a new stake in shares of Sage Therapeutics during the second quarter valued at approximately $153,000. Quest Partners LLC raised its holdings in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 6,618 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of Sage Therapeutics during the third quarter valued at approximately $146,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.